Aeterna Zentaris Inc. announced that it has, through a wholly-owned subsidiary, entered into a license and assignment agreement with a wholly-owned subsidiary of Strongbridge Biopharma plc to carry out development, manufacturing, registration and commercialization of Macrilen (macimorelin) in the United States and Canada. Aeterna Zentaris will receive an upfront cash payment of USD 24,000,000 from Strongbridge, and, for as long as Macrilen (macimorelin) is patent-protected, Aeterna Zentaris will be entitled to a 15% royalty on net sales up to USD 75,000,000 and an 18% royalty on net sales above USD 75,000,000. Following the end of patent protection in United States or Canada for Macrilen (macimorelin), Aeterna Zentaris will be entitled to a 5% royalty on net sales in that country. In addition, Aeterna Zentaris will also receive one-time payments from Strongbridge following the first achievement of the following commercial milestone events: Upon approval by the U.S. Food and Drug Administration (FDA) of a pediatric indication for Macrilen (macimorelin), Aeterna Zentaris will receive a one-time milestone payment of USD 5,000,000 from Strongbridge.